Merus incurred a $95.5 million net loss in Q3 2025, with revenues rising slightly to $12.2 million. Increased R&D costs, particularly for petosemtamab trials, drove higher operating expenses. Collaboration revenue from Gilead and Incyte partially offset the expenses. Cash reserves increased, bolstering liquidity into 2028.

Merus N.V. experienced a significant increase in total revenue for the first quarter of 2025, reaching $26.488 million, primarily driven by commercial material revenue and collaboration revenue. However, the company reported a substantial net loss of $96.474 million, an increase from the previous year, mainly due to higher operating expenses, particularly in research and development, and negative foreign exchange impacts.

Merus reported a net loss of $215.326 million for the full year 2024, an increase from the $154.939 million net loss in 2023. Total revenue for the full year was $36.133 million, down from $43.947 million in 2023. The company's cash and cash equivalents stood at $293.294 million as of December 31, 2024, with total assets at $782.693 million.

Merus N.V. announced financial results for the fourth quarter and full year ended December 31, 2019. The company's cash, cash equivalents and marketable securities totaled $241.8 million at the end of 2019, and the company expects to be funded into 2022.